There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
|Videos|December 10, 2020
The Elusive Work-Life Balance
Author(s)Andrew N. Wilner, MD
Is it possible to achieve balance between work and home life? Dr Wilner offers a solution.
Advertisement
Dr Wilner worked his first locum tenens assignment in 1982. He is Associate Professor of Neurology at the University of Tennessee Health Science Center, Memphis, Tennessee. Dr Wilner blogs at his website
Advertisement
Related to this article
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
The New, Impending Adult ADHD Guidelines
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
5